Fabienne Vervaat

Dr. Fabienne Vervaat

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2022 in European Heart Journal Open
Verified
Journal Article
Open access
PDF file
FVFabienne Vervaat
Fabienne Vervaat
AGAntal van der Gaag
Antal van der Gaag
KTKoen Teeuwen
Koen Teeuwen
HSHans van Suijlekom
Hans van Suijlekom
IWInge Wijnbergen
Inge Wijnbergen
The number of patients with coronary artery disease (CAD) who have persisting angina pectoris despite optimal medical treatment known as refractory angina pectoris (RAP) is growing. Current estimates indicate that 5–10% of patients with stable CAD have RAP. In absolute numbers, there are 50 000–100 000 new cases of RAP each year in the USA and 30 000–50 000 new cases each year in Europe. The term RAP was formulated in 2002. RAP is defined as a chronic disease (more than 3 months) characterized by diffuse CAD in the presence of proven ischaemia which is not amendable to a combination of medical therapy, angioplasty, or coronary bypass surgery. There are currently few treatment options for patients with RAP. One such last-resort treatment option is spinal cord stimulation (SCS) with a Class of recommendation IIB, level of evidence B in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes. The aim of this review is to give an overview of neuromodulation as treatment modality for patients with RAP. A comprehensive overview is given on the history, proposed mechanism of action, safety, efficacy, and current use of SCS.

1 July 2015 in Journal of Electrocardiology
Verified
Journal Article
Closed access
FVFabienne Vervaat
Fabienne Vervaat
TCThomas E. Christensen
Thomas E. Christensen
LSLoes Smeijers
Loes Smeijers
LHLene Holmvang
Lene Holmvang
PHPhilip Hasbak
Philip Hasbak
AGAnton P.M. Gorgels
Anton P.M. Gorgels

1 July 2025 in European Heart Journal
Verified
Journal Article
Open access
RSRanil de Silva
Ranil de Silva
KCKevin Cheng
Kevin Cheng
Timothy HenryTimothy Henry
Timothy Henry
DPDivaka Perera
Divaka Perera
VTViviany R Taqueti
Viviany R Taqueti
JKJuan Carlos Kaski
Juan Carlos Kaski
The diagnosis of refractory angina has conventionally been limited to patients with angina and ischaemia secondary to obstructive atherosclerotic epicardial coronary disease who experience persistent symptoms despite optimal pharmacological and revascularization therapies. It is now well-established that angina may also be caused by ischaemia resulting from coronary microcirculatory disorders, coronary vasospasm, and bridging in the absence of obstructive epicardial coronary disease or after “successful” revascularization. This increasingly prevalent and symptomatic group of patients, with both angina and demonstrable ischaemia, have been excluded from the conventional definition of refractory angina. In patients with obstructive epicardial coronary disease, disturbed microcirculatory and vasomotor function, amongst other ischaemic mechanisms, may account for continuing symptoms despite revascularization. Under-recognition of these mechanisms results in inadequate treatment and symptom persistence. In this review, a redefinition of refractory angina is proposed to include the full spectrum of patients experiencing persistent angina despite current maximal guideline-directed medical and revascularization therapies. Systematic approaches for comprehensive investigation are suggested to identify underlying mechanisms of ischaemia and stratify treatments accordingly. The complex needs of patients with refractory angina are likely best addressed by an inter-disciplinary Angina Heart Team with the aim of improving patient symptoms, quality of life, and clinical outcomes.

20 March 2023 in IJC Heart & Vasculature
Verified
Journal Article
Open access
FVFabienne Vervaat
Fabienne Vervaat
AGA. van der Gaag
A. van der Gaag
KTK. Teeuwen
K. Teeuwen
HSH. van Suijlekom
H. van Suijlekom
LDL. Dekker
L. Dekker
IWI.F. Wijnbergen
I.F. Wijnbergen
The number of patients with refractory angina pectoris (RAP), associated with poor quality of life, has been steadily increasing. Spinal cord stimulation (SCS) is a last resort treatment option leading to significant improvement in quality of life over a one year follow-up. The aim of this prospective, single-centre, observational cohort study is to determine the long-term efficacy and safety of SCS in patients with RAP. All patients with RAP who received a spinal cord stimulator from the period July 2010 up to November 2019 were included. In May 2022 all patients were screened for long-term follow-up. If the patient was alive the Seattle Angina (SAQ) and RAND-36 questionnaire were completed and if the patient had passed away cause of death was determined. The primary endpoint is the change in SAQ summary score at long-term follow-up compared to baseline. From July 2010 up to November 2019 132 patients received a spinal cord stimulator due to RAP. The mean follow-up period was 65.2 ± 32.8 months. Seventy-one patients completed the SAQ at baseline and long-term follow-up. The SAQ SS showed an improvement of 24.32U (95% confidence interval [CI]: 18.71 - 29.93; p < 0.001). The main findings of the study show that long-term SCS in patients with RAP leads to significant improvement in quality of life, significant reduction in angina frequency, significantly less use of short-acting nitrates and a low risk of spinal cord stimulator related complications over a mean follow-up period of 65.2 ± 32.8 months.

19 May 2020 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
FVFabienne Vervaat
Fabienne Vervaat
AGA. van der Gaag
A. van der Gaag
HSH. van Suijlekom
H. van Suijlekom
CBC. J. Botman
C. J. Botman
KTK. Teeuwen
K. Teeuwen
IWI. Wijnbergen
I. Wijnbergen
Aims: Spinal cord stimulation (SCS) is a treatment for patients with refractory angina pectoris (RAP) who remain symptomatic despite optimal medical therapy and without revascularisation options. Previous studies have shown that SCS improves the quality of life in this patient group and reduces the severity of the angina pectoris. The aim of this prospective, single-arm observational study is to show this effect in a single-centre cohort using a multidisciplinary team approach to the selection process, with a follow-up period of 1 year. Methods and results: Between July 2010 and March 2017, 87 patients with RAP referred to our centre received SCS. The Seattle Angina Questionnaire (SAQ) and RAND 36-Item Health Survey (RAND-36) were completed at baseline, prior to implantation, and 1 year post-implantation. After 1 year of follow-up there was a statistically significant decrease in the frequency of angina pectoris attacks from more than 4 times a day to 1–2 times a week (p < 0.001). The SAQ showed statistically significant improvement in four of the five dimensions: physical limitation (p < 0.001), angina frequency (p < 0.001), angina stability (p < 0.001) and quality of life (p < 0.001). The RAND-36 showed statistically significant improvement in all nine dimensions: physical functioning (p = 0.001), role/physical (p < 0.001), social functioning (p = 0.03), role/emotional (p < 0.05), bodily pain (p < 0.001), general health (p < 0.001), vitality (p < 0.001), mental health (p = 0.02) and health change (p < 0.001). Conclusion: This study showed a significant improvement in quality of life and reduction of angina pectoris severity after 1 year of follow-up in patients treated with SCS for RAP.

18 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MFMohamed El Farissi
Mohamed El Farissi
TMThomas P. Mast
Thomas P. Mast
Mileen van de KarMileen van de Kar
Mileen van de Kar
DDDaimy Dillen
Daimy Dillen
JDJesse Demandt
Jesse Demandt
LOLuuk C. Otterspoor
Luuk C. Otterspoor
The timely revascularization of an occluded coronary artery is the cornerstone of treatment in patients with ST-elevation myocardial infarction (STEMI). As essential as this treatment is, it can also cause additional damage to cardiomyocytes that were still viable before reperfusion, increasing infarct size. This has been termed “myocardial reperfusion injury”. To date, there is still no effective treatment for myocardial reperfusion injury in patients with STEMI. While numerous attempts have been made to overcome this hurdle with various experimental therapies, the common denominator of these therapies is that, although they often work in the preclinical setting, they fail to demonstrate the same results in human trials. Hypothermia is an example of such a therapy. Although promising results were derived from experimental studies, multiple randomized controlled trials failed to do the same. This review includes a discussion of hypothermia as a potential treatment for myocardial reperfusion injury, including lessons learned from previous (negative) trials, advanced techniques and materials in current hypothermic treatment, and the possible future of hypothermia for cardioprotection in patients with STEMI.